术前检出TP53突变的甲状腺结节病理诊断:三中心32例系列
研究分析4575例术前细针穿刺分子检测样本中36例(0.8%)检出TP53突变,其中32例有手术病理诊断。良性/低危肿瘤占34%,恶性风险在全队列为66%、Bethesda III-IV类为56%;TP53合并其他突变及拷贝数改变时恶性风险达100%。
要点
- TP53突变甲状腺结节中34%为良性/低危肿瘤,多数行全甲状腺切除。
- 全队列恶性风险66%,Bethesda III-IV类为56%。
- TP53合并其他突变及拷贝数改变时恶性风险100%。
核心结论
- 34%的TP53突变结节为良性/低危甲状腺肿瘤,且多数接受了全甲状腺切除。
- TP53突变合并其他突变及拷贝数改变时恶性风险显著升高至100%。
- 仅25%的TP53突变结节为ATA高危癌,在合适临床背景下可考虑甲状腺腺叶切除作为初始治疗。
研究设计与样本
- 三中心回顾性系列,从4575例术前细针穿刺分子检测样本中识别36例(0.8%)TP53突变,纳入32例有手术病理诊断者。
- 对30例进行 comprehensive 分子分析,将分子改变分为4组:TP53单独、TP53伴拷贝数改变、TP53伴其他突变无拷贝数改变、TP53伴其他突变及拷贝数改变。
主要发现
- 复核诊断:良性/低危肿瘤11例(34%),ATA低危复发癌7例(22%),ATA低-中危癌6例(19%),ATA高危癌8例(25%)。
- 全队列恶性风险66%,Bethesda III-IV类结节恶性风险56%。
- 11例良性/低危肿瘤均完整送检肿瘤包膜,64%行全甲状腺切除。
- 四组恶性风险分别为40%、44%、67%、100%;ATA高危癌频率分别为20%、11%、22%、43%。
- TP53合并其他突变及拷贝数改变组恶性风险(7/7,100%)高于TP53单独或仅伴拷贝数改变组(6/14,43%)(P = .018)。
关键数值与推荐
- TP53突变合并其他突变及拷贝数改变时恶性风险为100%(7/7)。
- TP53单独或仅伴拷贝数改变时恶性风险为43%(6/14)。
- 全队列恶性风险66%,Bethesda III-IV类56%。
- ATA高危癌仅占25%。
临床怎么用
- TP53突变甲状腺结节应结合是否合并其他突变及拷贝数改变综合评估恶性风险。
- TP53合并其他突变及拷贝数改变者恶性风险极高,需积极手术。
- 在合适临床背景下,TP53突变结节可考虑甲状腺腺叶切除作为初始治疗,以避免过度全切。
局限性
- 样本量小(32例),为回顾性三中心系列。
- 部分病例分子分析不全面(30/32例完成 comprehensive 分析)。
- 良性/低危肿瘤均完整送检包膜,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mutations in the tumor protein 53 gene (TP53 mutation) in thyroid nodules are quoted to confer a high (80%) probability of malignancy when detected on the ThyroSeq v3 genomic classifier if associated with other molecular alterations. However, TP53 mutation also occurs in benign and low-risk thyroid neoplasms. Thus, the risk of malignancy in nodules harboring TP53 mutation is not well characterized. METHODS: Of 4,575 molecularly profiled preoperative fine-needle aspiration samples, 36 (0.8%) were identified harboring TP53 mutation. The study included 32 cases in which the pathology diagnosis was obtained from surgical specimens. RESULTS: The reviewed diagnosis was benign/low-risk neoplasms in 11 (34%), carcinoma-American Thyroid Association low risk of recurrence in 7 (22%), carcinoma-American Thyroid Association low-intermediate risk in 6 (19%), and carcinoma-American Thyroid Association high risk in 8 (25%). In the entire cohort and the indeterminate fine-needle aspiration category (Bethesda III-IV), the risk of malignancy was 66% and 56%, respectively. All 11 cases with a reviewed diagnosis of benign or low-risk neoplasms had their tumor capsule submitted entirely for histologic examination, and 64% had total thyroidectomy. In 30 cases comprehensively molecularly profiled, the molecular alterations were substratified into 4 groups: TP53 mutation alone (n = 5, 17%), TP53 mutation with copy number alteration (n = 9, 30%), TP53 mutation with other mutations but no copy number alteration (n = 9, 30%), and TP53 mutation with other mutations and copy number alteration (n = 7, 23%). The risk of malignancy for each group was 40%, 44%, 67%, and 100%, respectively. The frequency of American Thyroid Association-high-risk malignancy, which would often lead to a recommendation for total thyroidectomy, was 20%, 11%, 22%, and 43%, respectively. The risk of malignancy was higher in cases with additional mutations and copy number alteration (7/7, 100%) than in those with TP53 alone or with concomitant copy number alteration only (6/14, 43%) (P = .018). CONCLUSION: Thirty four percent of nodules with TP53 mutation with or without concomitant molecular alterations were benign/low-risk thyroid neoplasms and treated by total thyroidectomy in the majority of cases. Risk of malignancy increased significantly to 100% when TP53 mutation co-occurred with other mutations and copy number alterations. Since American Thyroid Association high-risk carcinomas were found in only 25% of TP53-mutated nodules, thyroid lobectomy may be considered as the initial treatment, in the appropriate clinical context.
引用
- Lazim A, Alzumaili B, Xu B, et al. Pathologic diagnosis of thyroid nodules with preoperatively detected tumor protein 53 mutations: A tricenter series of 32 cases. Surgery. 2026. PMID: 42743661. doi:10.1016/j.surg.2026.110536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。